Upsher-Smith has entered into an exclusive agreement with Emphascience to support the development of a specialty branded generic product.
This collaboration is part of Upsher-Smith’s company-wide effort to grow its portfolio of products through strategic partnerships and product acquisitions, the company said.
Emphascience will develop the product exclusively for Upsher-Smith, while Upsher-Smith will manufacture, market and distribute it under its own label in the United States upon Food and Drug Administration approval. Financial terms related to the deal have not been disclosed.
“Upsher-Smith is committed to growing its ANDA portfolio through external programs and strategic partnerships that will drive volume to our new manufacturing facility,” said Rich Fisher, president and COO of Upsher-Smith.
“We look forward to working with Emphascience, a company that is well known for its development expertise as we continue to expand our portfolio with high-touch generic products that could fill unmet patient needs,” he said.
“We are excited to partner with such a well-regarded, trusted, quality-conscious and patient-focused pharmaceutical company as Upsher-Smith Laboratories to apply our technical skills and scientific acumen in designing and developing high quality, innovative medicines that truly impact patients’ lives,” said Rebanta Bandyopadhyay, president and CEO of Emphascience.
Upsher-Smith will open its world-class manufacturing facility in Maple Grove, Minn., later this year. The new 270,000-sq.-ft. facility will have fully up-to-date serialization and packaging capabilities, with capacity and capabilities that can support contract manufacturing for third parties.